Key result
Multicenter Latin American registry launches to evaluate heart failure epidemiology, guideline adherence, and clinical outcomes.
Why the study?
Although the COVID-19 pandemic disrupted healthcare delivery, delayed diagnoses, and altered comorbidity profiles, comprehensive post-pandemic data on HF epidemiology, diagnostic pathways, clinical outcomes, and guideline adherence across Latin America remain limited.
Observational
Yes
This planned multicenter observational study aims to characterize post-pandemic heart failure epidemiology, diagnostic barriers, clinical outcomes, and guideline-directed medical therapy adherence across Latin America.
Answers are grounded in this paper and cite their sources.
Highlights need for regional HF data; leaves open whether post-pandemic patterns alter outcomes or GDMT adherence.
Heart Failure in Post-Pandemic Latin America: Epidemiology, Diagnostic Challenges, Clinical Outcomes, and Adherence to International Guidelines Abstract Background: Heart failure (HF) remains a leading cause of morbidity, hospitalization, and mortality across Latin America. The COVID-19 pandemic disrupted healthcare delivery, delayed diagnoses, altered comorbidity profiles, and may have accelerated cardiovascular risk, yet comprehensive post-pandemic data on HF epidemiology, diagnostic pathways, outcomes, and guideline adherence in the region are limited. Objective: To characterize the epidemiology of HF in Latin America after the acute pandemic phase, identify persistent diagnostic challenges, evaluate clinical outcomes, and assess adherence to contemporary international HF guidelines in real-world practice. Methods: This multicenter observational study will analyze data from national registries, hospital databases, and ambulatory cohorts across representative Latin American countries. Adult patients with incident or prevalent HF (reduced, mildly reduced, and preserved ejection fraction) diagnosed or managed from 2022 onward will be included. Key variables encompass demographic and clinical characteristics, diagnostic modalities (natriuretic peptides, echocardiography, advanced imaging), etiology, comorbidity burden (including post-COVID sequelae), pharmacologic and device therapies, hospitalization rates, mortality, and quality-of-care indicators aligned with major international guidelines (e.g., ESC, AHA/ACC/HFSA). Multivariable analyses will examine predictors of adverse outcomes and gaps in guideline-directed medical therapy (GDMT). Subgroup evaluations will address disparities by country income level, urban/rural setting, sex, and socioeconomic status. Expected Results: The study will generate updated incidence and prevalence estimates, describe shifts in HF phenotype and etiology relative to pre-pandemic patterns, quantify diagnostic delays and resource-related barriers, report contemporary rates of GDMT implementation and clinical outcomes, and identify modifiable gaps in care. Conclusions: By providing region-specific post-pandemic evidence, this work aims to inform health-system prioritization, support targeted quality-improvement initiatives, and guide adaptation of international HF guidelines to the epidemiological, infrastructural, and socioeconomic realities of Latin America.
No takes yet. Share an insight, caveat, or question.
Camilo Fernández Bravo (2026) conducted an observational in Heart failure. Post-pandemic heart failure management and guideline adherence was evaluated on Epidemiology (incidence/prevalence), diagnostic pathways, guideline-directed medical therapy adherence, hospitalization rates, and mortality. This planned multicenter study of adult heart failure patients managed from 2022 onward across Latin America will evaluate epidemiology, guideline adherence, and clinical outcomes (no results yet).
Synapse has enriched 10 related papers. Consider them for comparative context: